← 返回

单细胞和空间转录组学揭示自然杀伤/T 细胞淋巴瘤的瘤内异质性和免疫逃逸

英文原题:Single-cell and spatial transcriptomics reveal intratumor heterogeneity and immune evasion in natural killer/T cell lymphoma.

查看英文原题

Single-cell and spatial transcriptomics reveal intratumor heterogeneity and immune evasion in natural killer/T cell lymphoma.

PubMed 2025/09/22(内容时间) iScience Q1 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤/T细胞淋巴瘤(NKTCL)是一种EB病毒相关恶性肿瘤,属于高度侵袭性非霍奇金淋巴瘤亚型。然而,其瘤内异质性及肿瘤微环境(TME)中的相互作用仍未得到充分理解。本研究利用单细胞和空间转录组学技术分析NKTCL患者组织,鉴定出五个具有不同功能通路、分化轨迹和空间分布的恶性元程序(MPs)。值得注意的是,MP3亚群出现于肿瘤分化早期阶段,以MYC信号通路过度激活为特征,并与不良预后相关。有趣的是,药物抑制脂肪酸结合蛋白5(FABP5)可导致c-Myc下调,并在体外和体内显著抑制肿瘤生长。此外,配体-受体相互作用分析揭示,肿瘤相关巨噬细胞(TAMs)可能促进免疫逃逸并抑制TME内的T细胞活性。总之,我们的研究阐明了NKTCL的细胞异质性和免疫景观,为治疗干预提供了潜在靶点。

展开英文摘要原文

Natural killer/T cell lymphoma (NKTCL), an Epstein-Barr virus-associated malignancy, is a highly aggressive subtype of non-Hodgkin lymphoma.

However, the intratumoral heterogeneity and the interaction within the tumor microenvironment (TME) remain insufficiently understood.

Here, we utilized single-cell and spatial transcriptomics to analyze tissues from NKTCL patients, identifying five malignant meta-programs (MPs) with distinct functional pathways, differentiation trajectories, and spatial distributions.

Notably, the MP3 subgroup emerges at the early stages of tumor differentiation, characterized by the hyperactivation of MYC signaling and an association with poor prognosis. Intriguingly, pharmacologic inhibition of fatty acid-binding protein 5 (FABP5) leads to the downregulation of c-Myc and significantly impairs tumor growth both in vitro and in vivo .

Furthermore, ligand-receptor interaction analysis reveals that tumor-associated macrophages (TAMs) may facilitate immune evasion and suppress T cell activity within the TME. Collectively, our findings elucidate the cellular heterogeneity and immune landscape of NKTCL, offering potential targets for therapeutic intervention.

论文信息

作者
Ma S、Huang B、Wang J、Lv R、Dai DL、Zhong Q、Xia Y、Liu P
单位
Department of Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.China
期刊
iScience2025 Oct 17
原文标识
PubMed 41142990 · DOI 10.1016/j.isci.2025.113626